Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06220604 · ClinicalTrials.gov registry record · Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.

Active
Registry status
Phase 3
Development phase
731
Enrollment target
20
Study locations

NCT06220604 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 731 participants, above the 400-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06220604, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
731 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Conditions Studied

Plaque Psoriasis

Interventions

  • DRUG Deucravacitinib
  • DRUG JNJ-77242113
  • DRUG JNJ-77242113 Matching Placebo
  • DRUG Deucravacitinib Matching Placebo

Study Locations (20)

California

  • California Dermatology & Clinical Research Institute - Encinitas
  • T Joseph Raoof Md Inc - Encino
  • UCSF Fresno - Fresno
  • University of California Los Angeles - Division of Dermatology - Los Angeles
  • Wallace Medical Group, Inc - Los Angeles
  • Dermatologist Medical Group of North County, Inc. - Oceanside

Florida

  • Miami Dermatology And Laser Institute - Miami
  • Bioclinical Research Alliance Inc. - Miami
  • Forcare Clinical Research Inc - Tampa

Michigan

  • University of Michigan - Ann Arbor
  • Great Lakes Research Group - Bay City
  • The Derm Institute of West Michigan - Caledonia

Kentucky

  • Skin Sciences, PLLC - Louisville
  • Qualmedica Research - Owensboro

Massachusetts

  • Metro Boston Clinical Partners - Brighton
  • ActivMed Practices and Research - Methuen

Arizona

  • Alliance Dermatology and MOHS Center P C - Phoenix

Georgia

  • Southeast Dermatology Specialists - Douglasville

Illinois

  • Arlington Dermatology - Rolling Meadows

Trial Details

FieldValue
Enrollment Target 731 participants
Start Date 2024-03-09
Est. Completion 2027-09-20
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06220604

The ClinicalTrials.gov registry entry for NCT06220604 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 731 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 400-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (83% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Deucravacitinib is the first listed.

NCT06220604 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT06220604 about?

NCT06220604 is a clinical study titled "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)". The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

What is the current status of trial NCT06220604?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 731 participants. The study started on 2024-03-09. Estimated completion is 2027-09-20.

What conditions does trial NCT06220604 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT06220604?

The interventions under investigation include: Deucravacitinib (DRUG), JNJ-77242113 (DRUG), JNJ-77242113 Matching Placebo (DRUG), Deucravacitinib Matching Placebo (DRUG).

Who is sponsoring clinical trial NCT06220604?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06220604 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plaque Psoriasis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.